LV12712A - Inhibitor and sulfobutylether-7-beta-cyclodextrin or 2-hydroxypropyl-beta-cyclodekstrin and method - Google Patents

Inhibitor and sulfobutylether-7-beta-cyclodextrin or 2-hydroxypropyl-beta-cyclodekstrin and method

Info

Publication number
LV12712A
LV12712A LV010101A LV010101A LV12712A LV 12712 A LV12712 A LV 12712A LV 010101 A LV010101 A LV 010101A LV 010101 A LV010101 A LV 010101A LV 12712 A LV12712 A LV 12712A
Authority
LV
Latvia
Prior art keywords
beta
cyclodextrin
ras
inhibitor
sulfobutylether
Prior art date
Application number
LV010101A
Other languages
English (en)
Other versions
LV12712B (lv
Inventor
Krishnaswamy S Raghavan
Timothy M Malloy
Sailesh A Varia
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of LV12712A publication Critical patent/LV12712A/lv
Publication of LV12712B publication Critical patent/LV12712B/lv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nanotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Plural Heterocyclic Compounds (AREA)
LVP-01-101A 1999-01-21 2001-07-04 RAS-FARNEZILTRANSFERĀZES INHIBITORA KOMPLEKSS UN 7-ø-CIKLODEKSTRĪNA SULFOBUTILĒTERIS VAI 2-HIDROKSIPROPIL-ø-CIKLODEKSTRĪNS UN METODES LV12712B (lv)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11664799P 1999-01-21 1999-01-21
PCT/US1999/030424 WO2000042849A1 (en) 1999-01-21 1999-12-21 COMPLEX OF RAS-FARNESYLTRANSFERASE INHIBITOR AND SULFOBUTYLETHER-7-β-CYCLODEXTRIN OR 2-HYDROXYPROPYL-β-CYCLODEXTRIN AND METHOD

Publications (2)

Publication Number Publication Date
LV12712A true LV12712A (lv) 2001-09-20
LV12712B LV12712B (lv) 2002-01-20

Family

ID=22368422

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-01-101A LV12712B (lv) 1999-01-21 2001-07-04 RAS-FARNEZILTRANSFERĀZES INHIBITORA KOMPLEKSS UN 7-ø-CIKLODEKSTRĪNA SULFOBUTILĒTERIS VAI 2-HIDROKSIPROPIL-ø-CIKLODEKSTRĪNS UN METODES

Country Status (33)

Country Link
US (1) US6218375B1 (lv)
EP (1) EP1143796A4 (lv)
JP (1) JP2002535253A (lv)
KR (1) KR100708360B1 (lv)
CN (1) CN1219517C (lv)
AR (1) AR022323A1 (lv)
AU (1) AU772204B2 (lv)
BG (1) BG105666A (lv)
BR (1) BR9916566A (lv)
CA (1) CA2359646C (lv)
CO (1) CO5160253A1 (lv)
CZ (1) CZ20012601A3 (lv)
EE (1) EE200100382A (lv)
GE (1) GEP20043214B (lv)
HK (1) HK1038865A1 (lv)
HU (1) HUP0105160A3 (lv)
ID (1) ID30139A (lv)
IL (1) IL144025A (lv)
LT (1) LT4893B (lv)
LV (1) LV12712B (lv)
MY (1) MY119700A (lv)
NO (1) NO20013585L (lv)
NZ (1) NZ511995A (lv)
PE (1) PE20001419A1 (lv)
PL (1) PL195280B1 (lv)
RU (1) RU2230062C2 (lv)
SK (1) SK9602001A3 (lv)
TR (1) TR200102109T2 (lv)
TW (1) TWI232752B (lv)
UA (1) UA67825C2 (lv)
UY (2) UY25986A1 (lv)
WO (1) WO2000042849A1 (lv)
ZA (1) ZA200104416B (lv)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI310684B (en) * 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
JP2003063965A (ja) * 2001-06-13 2003-03-05 Otsuka Pharmaceut Factory Inc 注射用シロスタゾール水性製剤
US6566347B1 (en) * 2001-08-22 2003-05-20 Duquesne University Of The Holy Ghost Controlled release pharmaceutical
US7074921B2 (en) * 2001-11-13 2006-07-11 Bristol Myers Squibb Company Process for the preparation of 3,7-disubstituted-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine compounds
KR100451485B1 (ko) 2002-03-28 2004-10-06 주식회사종근당 푸마질롤 유도체 또는 그 염의 포접 화합물, 및 이를포함하는 약제학적 조성물
US6869939B2 (en) * 2002-05-04 2005-03-22 Cydex, Inc. Formulations containing amiodarone and sulfoalkyl ether cyclodextrin
AU2003276648A1 (en) * 2002-06-17 2003-12-31 Bristol-Myers Squibb Company Benzodiazepine inhibitors of mitochondial f¿1?f¿0? atp hydrolase and methods of inhibiting f¿1?f¿0? atp hydrolase
US7157446B2 (en) * 2003-05-02 2007-01-02 Bristol Myers Squibb Company Complex of ras-farnesyltransferase inhibitor, a cyclodextrin, and ethanol
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
US20100204178A1 (en) 2006-10-02 2010-08-12 James Cloyd Novel parenteral carbamazepine formulation
EP2444090B1 (en) 2005-09-30 2018-12-12 Lundbeck Pharmaceuticals LLC Novel parenteral carbamazepine formulation
CN100503647C (zh) * 2005-11-02 2009-06-24 南京师范大学 羟丙基-磺丁基-β-环糊精及其制备方法、分析方法以及在药学上的应用
TW200806284A (en) * 2006-03-31 2008-02-01 Alcon Mfg Ltd Prenyltransferase inhibitors for ocular hypertension control and the treatment of glaucoma
BRPI0719096A2 (pt) * 2006-11-21 2013-12-03 Novartis Ag Formulação parenteral estavel contendo uminibidor de rsv de uma estrutura de benzodiazepina
PL3372605T3 (pl) 2008-10-22 2022-03-07 Array Biopharma Inc. Podstawione związki pirazolo[1,5-a]pirymidynowe jako inhibitory kinaz trk
RU2627460C2 (ru) 2010-05-26 2017-08-08 Нейрофиксиа Б.В. Составы 2-иминобиотина и их применение
WO2012034038A2 (en) * 2010-09-09 2012-03-15 H. Lee Moffitt Cancer Center And Research Institute, Inc. Dual inhibitors of farnesyltransferase and geranylgeranyltransferase i
WO2013052765A1 (en) * 2011-10-07 2013-04-11 Pisces Therapeutics Llc Malignant and non-malignant disease treatment with ras antagonists
CN105194685A (zh) * 2015-10-15 2015-12-30 重庆大学 磺胺脒的磺丁基醚-β-环糊精包合物及其粉针制剂
AU2016372396B2 (en) 2015-12-16 2022-04-14 Neurophyxia B.V. 2-iminobiotin for use in the treatment of brain cell injury
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
FI3439662T3 (fi) 2016-04-04 2024-09-04 Loxo Oncology Inc (s)-n-(5-((r)-2-(2,5-difluorifenyyli)pyrrolidin-1-yyli)pyratsolo[1,5-a]pyrimidin-3-yyli)-3-hydroksipyrrolidiini-1-karboksamidin nesteformulaatioita
PE20190437A1 (es) 2016-05-18 2019-03-27 Loxo Oncology Inc Procesos para la preparacion de (s)-n-(5-((r)-2-(2,5-difluorofenil)pirrolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidin-1-carboxamida y sales del mismo
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
US20210145816A1 (en) * 2019-11-15 2021-05-20 Cyclolab Cyclodextrin Research And Development Laboratory Ltd. Pharmaceutical formulation of lonafarnib with a sulfobutylether beta-cyclodextrin
KR20240096905A (ko) * 2021-12-15 2024-06-26 신라젠(주) 변형된 베타-사이클로덱스트린을 포함하는 약제학적 조성물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5630927A (en) * 1979-08-24 1981-03-28 Zeria Shinyaku Kogyo Kk Stabilization of guaiazulene and its derivative
US4371673A (en) * 1980-07-21 1983-02-01 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Water soluble forms of retinoids
US4596795A (en) * 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
JPH07165616A (ja) * 1993-12-09 1995-06-27 Hisamitsu Pharmaceut Co Inc シクロデキストリンの複合組成物及び複合化法
US6011029A (en) * 1996-02-26 2000-01-04 Bristol-Myers Squibb Company Inhibitors of farnesyl protein transferase
JPH1067639A (ja) * 1996-08-26 1998-03-10 Shiseido Co Ltd ビタミンｅ−ビタミンｃリン酸ジエステル／シクロデキストリン包接物及び該包接物を配合した皮膚外用剤

Also Published As

Publication number Publication date
BG105666A (en) 2002-04-30
UY25987A1 (es) 2000-09-29
EP1143796A4 (en) 2002-03-20
TR200102109T2 (tr) 2001-12-21
UA67825C2 (uk) 2004-07-15
IL144025A0 (en) 2002-04-21
LT4893B (lt) 2002-02-25
ID30139A (id) 2001-11-08
JP2002535253A (ja) 2002-10-22
ZA200104416B (en) 2002-05-29
TWI232752B (en) 2005-05-21
MY119700A (en) 2005-06-30
KR20010101611A (ko) 2001-11-14
HUP0105160A3 (en) 2003-01-28
WO2000042849A1 (en) 2000-07-27
CO5160253A1 (es) 2002-05-30
CA2359646C (en) 2008-12-02
PE20001419A1 (es) 2001-02-21
GEP20043214B (en) 2004-04-26
IL144025A (en) 2004-05-12
NO20013585L (no) 2001-09-04
SK9602001A3 (en) 2002-06-04
KR100708360B1 (ko) 2007-04-17
PL366338A1 (en) 2005-01-24
NZ511995A (en) 2003-11-28
EE200100382A (et) 2002-12-16
HK1038865A1 (zh) 2002-04-04
UY25986A1 (es) 2000-09-29
AR022323A1 (es) 2002-09-04
CN1333651A (zh) 2002-01-30
RU2230062C2 (ru) 2004-06-10
BR9916566A (pt) 2001-11-13
NO20013585D0 (no) 2001-07-20
CA2359646A1 (en) 2000-07-27
AU2374000A (en) 2000-08-07
CN1219517C (zh) 2005-09-21
AU772204B2 (en) 2004-04-22
LT2001064A (en) 2001-10-25
LV12712B (lv) 2002-01-20
CZ20012601A3 (cs) 2002-05-15
PL195280B1 (pl) 2007-08-31
US6218375B1 (en) 2001-04-17
EP1143796A1 (en) 2001-10-17
HUP0105160A2 (hu) 2002-05-29

Similar Documents

Publication Publication Date Title
LV12712A (lv) Inhibitor and sulfobutylether-7-beta-cyclodextrin or 2-hydroxypropyl-beta-cyclodekstrin and method
NL300927I1 (nl) tivozanib of een zout of hydraat ervan, in het bijzonder het hydrochloride-monohydraat
MY118904A (en) 4-oxo-1, 4-dihydro-3-quinolinecarboxamides as antiviral agents
DK0590919T3 (da) Terapeutiske midler mod Parkinsons sygdom
PT1076663E (pt) Derivados funcionalizados de alquilo e alcenilo de cadeia lateral de glicinamidas como inibidores de farnesil transferase
EE200200148A (et) Kinasoliini derivaadid, nende valmistamise meetodning kasutamine
WO2004052893A3 (en) Substituted dihydropyrano indole-3,4-dione derivatives and 3-oxoacetic acid substituted 2-hydroxymethylindole derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
CY1107001T1 (el) Αζωτουχα ετεροκυκλικα παραγωγα καρβοξαμιδιου ή αλας αυτων ως αντιϊκοι παραγοντες
RS20050182A (en) Derivatives of dioxane-2-alkyl carbamates,preparation method thereof and application of same in therapeutics
DK1044967T3 (da) 2-pyridinylguanidinurokinaseinhibitor
NO934792L (no) Xantinderivater
CY1110284T1 (el) Παραγωγα της 2-αμινο-4-πυριδυλομεθυλο-θειαζολινης και η χρηση τους ως αναστολεις της επαγωγιμης συνθασης νο
IT1250749B (it) Composti eterociclici ad attivita' a ii antagonista
DE69414019D1 (de) Bicyclische Stichstoff enthaltende Derivate als Prolyl-Endopeptidase Inhibitoren
TW350838B (en) Quinoline derivatives
BG106048A (en) 6-[[(aryl and heteroaryl)oxy]methyl]naphthalene-2-carboximidamide derivatives, preparation and therapeutic application thereof
ECSP003322A (es) COMPLEJO DEL INHIBIDOR DE RAS- FARNESIL TRANSFERASA Y SULFOBUTILETER -7-ß- CICLODEXTRINA O 2- HIDROXIPROPIL - ß - CICLODEXTRINA Y METODO
TH49472A3 (th) สารเชิงซ้อนของสารยับยั้งราส-ฟาร์นีซิลทรานส์เฟอเรสและซัลโฟบิวทิลอีเธอร์-7-เบตา-ไซโคลเดกซ์ทริม หรือ 2-ไฮดรอกซีโพรพิล-เบตา-ไซโคลเดกซ์ทรินและวิธีการ
NO910198L (no) Anti-inflammatoriske 4-aminofenolderivater.